Last reviewed · How we verify

duration of the antibiotic therapy

Tourcoing Hospital · FDA-approved active Small molecule Quality 2/100

The antibiotic therapy marketed by Tourcoing Hospital holds a niche position in the current market, with a key composition patent set to expire in 2028. The primary strength lies in its established market presence and ongoing revenue generation, though specific financial details are not disclosed. The main risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameduration of the antibiotic therapy
Also known as- Rifampin, - Levofloxacin, - Doxycycline, - Trimethoprim- sulfamethoxazole, - Fusidic acid
SponsorTourcoing Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: